William Blair Initiates Coverage On Palvella Therapeutics with Outperform Rating
William Blair analyst Alethia Young initiates coverage on Palvella Therapeutics (NASDAQ:PVLA) with a Outperform rating.
Stocks · News reference
Full Transcript: Palvella Therapeutics Q2 2026 Earnings Call
Palvella Therapeutics (NASDAQ:PVLA) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs. For real-time access
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Amazon To $310? Here Are 10 Top Analyst Forecasts For Monday
Analysts raised targets for CRBG, MTN, CRM and FSLR, while cutting targets for PVLA, SPOT and AMZN; CRM and FSLR were upgraded.
Palvella Says QTORIN Rapamycin Systemic Exposure At Least 40-Fold Lower Than Published Oral Sirolimus Data In Phase 3 Substudy
HC Wainwright & Co. Maintains Buy on Palvella Therapeutics, Lowers Price Target to $246
HC Wainwright & Co. analyst Andrew S. Fein maintains Palvella Therapeutics (NASDAQ:PVLA) with a Buy and lowers the price target from $270 to $246.